版本:
中国

BRIEF-Immunomedics says sacituzumab govitecan active in patients with metastatic small-cell lung

April 5 Immunomedics Inc-

* Immunomedics reports sacituzumab govitecan (immu-132) is active in patients with metastatic small-cell lung cancer who are sensitive or resistant to first-line chemotherapy

* Immunomedics Inc - sixty percent of patients showed tumor shrinkage from baseline measurements using computed tomography in phase 2 study

* Immunomedics Inc - on an intention-to-treat basis orr was 14% median response duration was 5.7 months in study

* Immunomedics - data shows there was no statistical difference in orr, pfs or os between patients who were chemosensitive or chemoresistant to first-line chemo Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐